{"preliminary_commentary":{"by_channel":{"youtube":1,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"START-001","nct_id":"NCT05592626","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=start-001-nct05592626. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"START-001","arms":[{"description":"Dose Escalation; Intervention: Drug: STAR0602, Invikafusp alfa","label":"Phase 1: Advanced Solid Tumors","type":"EXPERIMENTAL"},{"description":"Dose Expansion; Recommended Phase 2 Dose (RP2D) identified from Phase 1 will be used in Phase 2; Intervention: Drug: STAR0602, Invikafusp alfa","label":"Phase 2: Advanced Solid Tumors","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors","Genital Neoplasm, Female","Urogenital Neoplasms","Lung Neoplasm","Neoplasms by Site","Papillomavirus Infection","Epstein-Barr Virus Infections","Carcinoma","Neoplasms","Vulvar Neoplasms","Vulvar Diseases","Abdominal Neoplasm","NSCLC (Non-small Cell Lung Cancer)","Colorectal Cancer"],"enrollment":{"count":366,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"STAR0602","otherNames":["Invikafusp alfa"],"type":"DRUG"},{"name":"Irinotecan (Camptosar)","otherNames":["Camptosar"],"type":"COMBINATION_PRODUCT"},{"name":"Docetaxel (Taxotere)","otherNames":["Taxotere"],"type":"COMBINATION_PRODUCT"}],"last_update":"2026-08-11","lead_sponsor":"Marengo Therapeutics, Inc.","official_title":"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1","timeFrame":"Cycle 1 (Cycle length= 28 days)"},{"measure":"Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 3 years"},{"measure":"Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)","timeFrame":"Up to 3 years"}],"references":[],"start_date":{"date":"2023-01-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05592626"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/start-001-nct05592626"}